[Abstract] Objective To analyze the efficacy of taurochenodeoxycholic acid on intestinal inflammation and to provide a theoretical basis for the treatment of acute and chronic inflammation of the intestinal tract. Methods The in vitro and in vivo experimental groups were blank group, LPS group and LPS+TCDCA group. In the in vitro experiments, MTT method was firstly applied to screen the appropriate working concentration of TCDCA, and then macrophage LPS stimulation was given to the LPS group, and LPS and TCDCA stimulation were given to the LPS+TCDCA group successively, and the expression of inflammation-related mRNAs and proteins were examined by RT-qPCR and Western blot. In the in vivo experiments, the LPS group was injected with LPS solution intravenously through the ear margin of rabbits, and the LPS+TCDCA group was treated as above and then fed with TCDCA solution through drinking water. Histopathological alterations of the samples were assessed by HE staining, periodic acid-Schiff staining and Alcian blue-nuclear solid red staining after experimental sampling. Results The results of in vitro experiments showed that the expression of pro-inflammatory indexes was significantly reduced and the expression of anti-inflammatory indexes was elevated in macrophages in the LPS+TCDCA group compared with that in the LPS group. In the in vivo experiments, the results of HE staining showed that the inflammation of intestinal tissues was relieved, and the results of periodic acid-Schiff staining and Alcian blue-nucleic solid red staining showed that the number of cup cells and the secretion of acidic and neutral mucins in the LPS+TCDCA group increased compared with that in the LPS group. Conclusion: Taurine deoxycholic acid (TCDCA) alleviates intestinal tissue inflammation and reduces intestinal inflammatory damage caused by LPS by decreasing the expression of inflammatory factors.